Citation

Ledbetter M. Neuropsychiatr. Dis. Treat. 2006; 2(4): 455-466.

Copyright

(Copyright © 2006, Dove Press)

DOI

10.2147/nedt.2006.2.4.455

PMID

unavailable

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common chronic condition with childhood onset that can continue into adulthood. Medication is a fundamental element in the management of this disorder. Atomoxetine is the newest nonstimulant medication approved by the United States Food and Drug Administration (FDA) for the treatment of ADHD. It is the only nonstimulant medication approved by the FDA for treatment of adult ADHD. Atomoxetine is a norepinephrine reuptake inhibitor that selectively inhibits the presynaptic norepinephrine transporter. A growing body of literature supports the use of atomoxetine both in children and adults with ADHD. This paper summarizes information from the literature about atomoxetine, including pharmacokinetics, pharmacodynamics, clinical trials, dosing, and side-effects. © 2006 Dove Medical Press Limited. All rights reserved.

Language: en

Keywords

human; suicide; Review; insomnia; abdominal pain; ADHD; anxiety; clinical trial; drug overdose; fatigue; Atomoxetine; article; anorexia; vomiting; rating scale; amfebutamone; citalopram; clomipramine; fluoxetine; food drug interaction; paroxetine; sertraline; tachycardia; somnolence; appetite disorder; urine retention; gastrointestinal symptom; edema; confusion; drug safety; placebo; food and drug administration; drug blood level; seizure; patient compliance; drug efficacy; nausea; ethnic difference; drug withdrawal; disease exacerbation; irritability; onset age; cardiovascular disease; mania; chlorpromazine; side effect; attention deficit disorder; escitalopram; erectile dysfunction; heart rate; allergic reaction; methylphenidate; QT prolongation; quinidine; flu like syndrome; pharyngitis; drug absorption; drug half life; body weight; drug approval; nervousness; blood pressure; dizziness; drug eruption; rhinitis; urticaria; libido disorder; atomoxetine; tic; drug bioavailability; drug induced headache; drug dose increase; drug dose titration; jaundice; drug excretion; dysmenorrhea; alpha adrenergic receptor; drug selectivity; hydroxyzine; Nonstimulants; pulse pressure; salbutamol